Fertility Drugs Market Size, Share, Growth and Forecast, 2025-2035

Ovarian stimulation and ovulation induction drive demand

The global fertility drugs market was valued at USD 5.40 billion in 2025 and is projected to increase from USD 5.75 billion in 2026 to USD 10.13 billion by 2035, registering a CAGR of 6.49% during 2026–2035. Demand comes from couples and individuals treated for ovulation disorders, unexplained infertility and male factor infertility, and from clinics that use hormone injections to stimulate the ovaries before in vitro fertilization. North America held the largest regional share, 36.0% in 2025, because IVF cycles there use high doses of branded gonadotropins at high list prices. Asia Pacific is the fastest-growing region at 7.73% a year, as China, India and Japan expand fertility clinics and approve local recombinant hormones. The main commercial change came in October 2025, when EMD Serono agreed with the U.S. government to sell its core IVF medicines directly to patients at steep discounts.

Which hormones and tablets for conception are counted?

The market counts manufacturer revenue from prescription medicines used to treat infertility in women and men. It covers gonadotropins such as follicle-stimulating hormone and human chorionic gonadotropin, oral ovulation inducers, GnRH analogues used in stimulation cycles, dopamine agonists and luteal phase support. Buyers include fertility clinics, hospital and retail pharmacies, specialty and online pharmacies, insurers and patients paying out of pocket.

The scope excludes IVF laboratory equipment, culture media, clinic procedure fees, fertility tests and dietary supplements. Hormonal contraceptives and menopause hormone therapy are left out, even where the same molecules appear, because they are not prescribed to achieve pregnancy.

Gonadotropins and injectables hold most of the value

Why do gonadotropins hold the largest share?

Based on drug class, the market is categorized into gonadotropins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), dopamine agonists and other drug classes. Gonadotropins led with a 52.0% share of 2025 value, because IVF and intrauterine insemination cycles need several days of high-priced hormone injections. Aromatase inhibitors grow fastest at 7.26% a year, as clinicians use low-cost oral letrozole for ovulation induction in women with polycystic ovaries.

How do injections and tablets divide value?

Based on route of administration, the market is categorized into oral and injectable products. Injectable products led with a 68.0% share of 2025 value, because gonadotropins, GnRH antagonists and trigger shots are all given by injection. Injectable products also grow fastest at 6.63% a year, as more IVF cycles in Asia raise the use of prefilled hormone pens.

Why do treatments for women dominate spending?

Based on gender, the market is categorized into female and male patients. Female patients led with an 88.0% share of 2025 value, because ovarian stimulation, ovulation induction and luteal support are all given to women, even when the cause lies with the male partner. Male patients grow fastest at 7.28% a year, as hormone therapy for low sperm production gains wider clinical use.

Where do patients obtain fertility medicines?

Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, online pharmacy and others. Hospital Pharmacy led with a 38.0% share of 2025 value, because many IVF clinics sit within hospitals that dispense stimulation medicines. Online Pharmacy grows fastest at 8.12% a year, as direct-to-patient sales and home delivery of cold-chain pens expand.

Common infertility, delayed parenthood and wider IVF access

How does common infertility sustain demand?

Infertility is far more common than many health systems assume, which keeps a large pool of patients seeking treatment. In April 2023, the WHO estimated that around 17.5% of the adult population, roughly 1 in 6 people worldwide, experience infertility during their lives. Lifetime prevalence was similar in high-income and in low- and middle-income countries, at 17.8% and 16.5%. Because the condition affects every region, demand for ovulation inducers and stimulation hormones is broad rather than concentrated in wealthy markets.

Why does delayed parenthood raise hormone use?

Many couples now try for a first child later in life, when natural fertility is lower and ovarian reserve has declined. Older patients often need higher hormone doses and more stimulation cycles to retrieve enough eggs for IVF. Many also pursue egg freezing and embryo banking, which uses the same stimulation protocols before any pregnancy attempt. As a result, average gonadotropin use per patient rises in North America, Europe and East Asia, lifting value even where birth rates fall.

Download Free Sample

How does new global guidance widen treatment?

Public health bodies are pushing countries to include fertility care in national health systems, which brings new patients into treatment. On Nov. 28, 2025, the WHO issued its first global guideline for the prevention, diagnosis and treatment of infertility, with 40 recommendations that favor cost-effective options. The WHO noted that a single IVF round can cost double the average annual household income in some settings. This guidance supports wider use of affordable oral ovulation inducers before costly IVF.

Why do PCOS and ovulation disorders add volume?

Ovulation disorders are one of the most frequent causes of female infertility, and they are usually treated first with tablets rather than injections. Women with polycystic ovary syndrome often receive letrozole or clomiphene for several cycles before moving to gonadotropins. This step-up approach creates high unit volume for low-cost oral products. In turn, patients who do not respond move on to injectable protocols, which carry much higher value per cycle. Because the WHO counts 1 in six adults affected, even modest gains in diagnosis add many patients.

Lower IVF prices, biosimilar FSH and direct patient sales

Why are IVF medicine prices shifting lower?

Governments and manufacturers are shifting IVF medicine pricing toward direct, discounted sales to patients who pay out of pocket. On Oct. 16, 2025, EMD Serono agreed with the U.S. government to sell Gonal-f, Ovidrel and Cetrotide directly to eligible patients, with an 84% discount off list prices when all three are used in a typical protocol. The company also joined the TrumpRx.gov platform planned for January 2026. Lower prices can raise cycle numbers while reducing revenue per cycle.

How are biosimilar hormones emerging in Asia?

Local makers of recombinant follicle-stimulating hormone are emerging in China and India, adding lower-cost supply to a field long led by a few originators. In June 2026, Livzon received a Drug Registration Certificate from China's National Medical Products Administration for its recombinant human follitropin injection. The same report counted four imported and four domestic recombinant follitropin products in China. This rise in local supply supports wider IVF access at lower prices across Asia Pacific.

Download Free Sample

Where is the opening in male infertility?

Male infertility offers a clear opening, because men are often diagnosed late and have fewer approved medicine options than women. Hormone therapy with human chorionic gonadotropin and follicle-stimulating hormone can support sperm production in men with hormone deficiency. Better semen testing and growing awareness among urologists bring more men into care. Companies that develop evidence for male indications can capture a fast-growing group of patients.

Can wider insurance cover open new IVF demand?

Expanding insurance and employer cover for IVF offers an opening, because cost remains the main reason couples delay or stop treatment. When public or employer plans pay for stimulation medicines, clinics run more cycles and patients complete more transfers through assisted reproductive technology. Employer fertility benefits in the U.S. and public funding in parts of Europe and Asia already show this effect. As a result, suppliers gain volume wherever public or employer coverage widens.

Out-of-pocket costs, uneven coverage and cycle risks

How do out-of-pocket costs limit treatment?

Most patients in many countries pay for fertility medicines and clinic fees themselves, which limits how many cycles they can afford. The WHO reports that, in many countries, tests and treatments for infertility are paid for out of pocket, often resulting in catastrophic financial expenditure. Patients who cannot pay stop after one cycle or never start. Lower drug prices and public funding programs help, but progress varies widely by country.

Why does uneven coverage slow uptake?

Insurance rules for infertility differ sharply between countries, states and employers, which creates uneven demand for stimulation medicines. Some plans cover diagnosis but not IVF, while others cap the number of funded cycles or set age limits. Patients in uncovered areas travel abroad or choose cheaper protocols with lower hormone doses. This patchwork makes demand hard to forecast and slows uptake of higher-priced branded products.

What clinical risks affect stimulation protocols?

High-dose ovarian stimulation can cause ovarian hyperstimulation syndrome and multiple pregnancies, which raise safety concerns for patients and clinics. Doctors respond with milder protocols, GnRH antagonist cycles and single embryo transfer, which can reduce total hormone use per patient. These safety practices protect patients but limit volume growth for gonadotropins. In turn, makers focus on dosing tools that match treatment to each patient.

How does cold-chain supply affect access?

Many injectable fertility medicines need refrigerated storage and careful handling from factory to patient, which adds cost. Pharmacies and clinics in rural areas of Asia, Africa and Latin America may lack reliable cold storage. Shortages or delivery delays can force clinics to postpone stimulation cycles at short notice. As a result, suppliers invest in room-temperature pens and specialty pharmacy networks to protect patient access.

North America leads while Asia Pacific grows fastest

North America leads on IVF cycles and prices

North America held a 36.0% share of 2025 value and grows at 6.03% a year through 2035. The U.S. leads spending, because IVF protocols use branded gonadotropins at high list prices and many patients pay out of pocket. The October 2025 agreement that cut EMD Serono's direct prices to patients may increase cycle numbers. However, lower prices per cycle hold value growth below the global rate.

Europe balances public funding and generics

Europe held a 30.0% share of 2025 value and grows at 5.83% a year, the slowest pace among the five regions. Spain, the U.K., France, Germany and Italy account for most demand, with public funding for IVF in several countries. Biosimilar follitropin alfa products are already used across the region. However, tender pricing and national price controls keep value growth modest.

Download Free Sample

Asia Pacific grows on clinic expansion

Asia Pacific held a 24.0% share of 2025 value and is the fastest-growing region at 7.73% a year. China and India are adding fertility clinics quickly, and local producers such as Livzon, Intas Pharmaceuticals, Mankind Pharma and Sun Pharmaceutical supply hormones and oral agents. In June 2026, Livzon gained Chinese approval for a recombinant follitropin injection. As incomes rise, more couples in China and India pay for stimulation cycles.

Latin America relies on private clinics

Latin America held a 6.0% share of 2025 value and grows at 6.93% a year through 2035. Brazil, Mexico and Argentina account for most demand, with private clinics serving patients who pay out of pocket. Currency swings raise the cost of imported hormones and limit cycle numbers.

Gulf IVF clinics lead a small regional base

The Middle East & Africa held a 4.0% share of 2025 value and grows at 7.03% a year. Gulf states lead spending, with private IVF clinics and some public support for fertility care. Across much of Africa, access remains limited to oral ovulation inducers.

Download Free Sample

Pricing deals, guidance and approvals since 2025

Recombinant hormones and simpler pens reshape stimulation

• Recombinant FSH is produced in cell lines rather than extracted from urine, which gives consistent purity and dosing between batches.
• Biosimilar follitropin alfa offers the same molecule as the original product at lower prices, which widens access in Europe and Asia.
• Prefilled pens let patients inject precise hormone doses at home, which reduces clinic visits during stimulation cycles.
• GnRH antagonist protocols shorten stimulation and lower the risk of ovarian hyperstimulation compared with longer agonist protocols.
• Combined FSH and LH therapy supplies both hormones in one injection for patients with low natural luteinizing hormone.

Hormone specialists and generic makers share the field

Competition in fertility medicines splits between hormone specialists, large diversified drugmakers and generic producers. EMD Serono, Ferring Pharmaceuticals and Organon & Co. lead in gonadotropins and GnRH analogues used for IVF, and Organon makes Follistim AQ. Sun Pharmaceutical agreed in April 2026 to acquire Organon for USD 14 per share in a deal valued at USD 11.75 billion, which would add a central IVF hormone to an Indian-based group. Merck & Co., Pfizer, Sanofi, Novartis, Bayer and Abbott Laboratories hold women's health and hormone products used in reproductive care, while Besins Healthcare focuses on progesterone and hormone therapy. Teva Pharmaceutical, Intas Pharmaceuticals, Mankind Pharma and Livzon supply generic and biosimilar products at lower prices. Because pricing deals and biosimilars cut revenue per cycle, companies compete on supply reliability, dosing devices and clinic relationships.

Companies profiled and their roles in this market

Access policy, not new targets, sets the growth pace

Credence Research's view is that access policy, rather than new drug targets, will set the growth pace in fertility medicines through 2035. Gonadotropins keep most of the value, but direct-to-patient discounts in the U.S. and biosimilar follitropin in Asia lower revenue per cycle. Wider insurance cover and WHO guidance should raise the number of treated patients, which offsets lower prices. Companies with reliable cold-chain supply, home-use pens and strong clinic ties are best placed, while low-cost producers in India and China gain share in volume terms.

How the 2025 baseline and forecast were built

The report uses 2025 as the base year and forecasts market value to 2035, with growth rates stated for 2026–2035. Market values come from the Credence Research market model, which combines treated patient numbers, stimulation and ovulation induction cycles, typical dosing and average selling prices by region and channel. Splits by drug class, route of administration, gender, distribution channel and region are Credence Research estimates. Sources used include WHO infertility estimates and guidance, regulator decisions in China, and company announcements. No primary interviews or surveys were used to build the estimates in this report.

Biosimilars and cheaper cycles widen treatment by 2035

By 2035, the fertility drugs market reaches USD 10.13 billion, with more patients treated at lower prices per cycle. Gonadotropins remain the largest drug class as IVF expands in China, India and the Gulf states. Oral ovulation inducers gain volume as guidance favors cost-effective first steps. Online and direct-to-patient channels take a larger share of refill and home delivery orders. Biosimilar follitropin products spread across Asia and Europe, while consolidation such as the planned Sun Pharmaceutical purchase of Organon reshapes the supplier base.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.